Showing results (1-10 of 192) with videos related to
Sort By:
Pageof 20
Current Opinion in Rheumatology|September 10, 2003
Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritisShumpei YokotaPediatrics International : Official Journal of the Japan Pediatric Society|March 19, 2002
Mizoribine: mode of action and effects in clinical useShumpei YokotaNihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|May 1, 2008
[Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis]Shumpei YokotaNihon Rinsho. Japanese Journal of Clinical Medicine|November 19, 2003
[Influenza-associated encephalopathy--pathophysiology and disease mechanisms]Shumpei YokotaNihon Rinsho. Japanese Journal of Clinical Medicine|July 24, 2007
[Biologic response modifiers for juvenile idiopathic arthritis]Shumpei YokotaExpert Review of Clinical Immunology|September 11, 2010
Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritisShumpei Yokota, Tadamitsu KishimotoKansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|April 24, 2004
[Evaluation of Streptococcus pneumoniae urinary antigen test in healthy children with nasopharyngeal pneumococcal carriage]Akiyoshi Nariai, Shumpei YokotaPediatrics International : Official Journal of the Japan Pediatric Society|October 30, 2015
Inadequate sociomedical evaluation of possible abusive head trauma in YokohamaAtsuo Sato, Nobuyuki Kikuchi, Shumpei YokotaJournal of Cancer Research and Clinical Oncology|January 19, 2008
Increased chemosensitivity and elevated reactive oxygen species are mediated by glutathione reduction in glutamine deprived neuroblastoma cellsSakurako Izaki, Hiroaki Goto, Shumpei YokotaTherapeutic Advances in Musculoskeletal Disease|December 11, 2012
Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritisShumpei Yokota, Toshio Tanaka, Tadamitsu KishimotoPageof 20